SENORES1,468.00

Senores Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹6,760 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations103.0114.2138.0161.8174.6175.2180.2
Other Income5.211.83.45.43.817.72.8
Total Income108.2126.0141.4167.2178.3192.9183.0
Expenses
+ Cost of Materials Consumed23.120.929.446.137.027.131.2
+ Purchases of Stock-in-Trade22.129.127.611.037.935.734.0
+ Changes in Inventories-4.57.54.4-0.0-7.83.50.6
+ Employee Benefit Expense19.014.621.729.630.730.329.9
+ Finance Costs6.25.35.06.25.38.57.2
+ Depreciation & Amortisation4.25.26.08.17.99.39.9
+ Other Expenses17.622.720.825.622.931.230.8
Total Expenses87.7105.3114.9126.5133.7145.5143.6
EBITDA25.719.434.249.554.047.553.8
EBIT21.514.228.241.446.238.243.8
Profit
PBT before Exceptional Items20.520.726.540.644.647.439.5
Pretax Income20.520.726.540.644.647.439.5
+ Current Tax6.16.74.911.48.6-5.09.8
+ Deferred Tax-2.0-4.00.4-0.82.415.7-0.8
Tax Expense4.12.75.310.511.010.79.0
Net Income16.418.021.230.133.636.730.5
+ Net Income — Continuing Ops16.418.021.230.133.636.730.5
+ Other Comprehensive Income-2.2-0.10.5-8.4-4.841.90.5
Total Comprehensive Income14.217.921.721.728.878.631.0
Net Income to Common17.219.732.431.70.030.7
Minority Interest-0.81.5-2.31.90.0-0.3
Per Share
Basic EPS5.043.814.606.547.297.966.61
Diluted EPS5.043.814.606.547.297.966.60
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.10.5-8.4-4.841.90.5
+ Items NOT to be Reclassified to P&L0.1-0.1-0.10.2
+ Tax on Items NOT to be Reclassified-0.0-0.00.10.0
+ Tax on Items NOT to be Reclassified — alt tag0.0
+ Items to be Reclassified to P&L-2.2-4.741.80.5
+ Tax on Items to be Reclassified0.1-0.58.30.00.00.0
Comprehensive Income — Owners of Parent15.320.125.728.00.00.5
Comprehensive Income — Non-controlling Interests-1.11.6-4.00.80.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations5.043.814.606.547.297.966.61
Diluted EPS — Continuing Operations5.043.814.606.547.297.966.60
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit62.356.876.6104.7107.5109.0114.5
Gross Margin %60.4949.6955.5364.7161.6162.2063.53
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)20.520.726.540.644.647.439.5
Net Income Adj (tax-effected)16.418.021.230.133.636.730.5
EPS Adj5.043.814.606.547.297.966.61
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital46.146.146.146.146.146.146.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.